China: Anji Pharma, an emerging global medicines company, has closed a US$70m Series B financing round to seed its oncology pipeline and continue trials of its two late-stage clinical programmes in metabolic disorders. The Series B round was solely invested by CR Capital, a China-based venture capital firm with a growing life science investment footprint…
Home Healthcare Markets International Private finance: iOmx Therapeutics, Micreos, CBMG Holdings, MFine, Open Stent Solution, Anji...